Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atezolizumab · 1 trial · 1 indication
ORR, defined as the proportion of participants with a complete response or partial response on two consecutive occasions \>=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| Stage 1: Atezolizumab + Bevacizumab | ACTIVE_COMPARATOR | Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Atezolizumab + Bevacizumab + Tiragolumab | EXPERIMENTAL | Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Atezolizumab + Bevacizumab + Tocilizumab | EXPERIMENTAL | Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Atezolizumab + Bevacizumab + TPST-1120 | EXPERIMENTAL | Participants will receive atezolizumab plus bevacizumab plus TPST-1120 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Tobemstomig 2100 mg Q2W + Bevacizumab | EXPERIMENTAL | Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Tobemstomig 600 mg Q3W + Bevacizumab | EXPERIMENTAL | Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Tobemstomig 1200 mg Q3W + Bevacizumab | EXPERIMENTAL | Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Atezolizumab + Bevacizumab + ADG126 | EXPERIMENTAL | Participants will receive atezolizumab plus bevacizumab plus ADG126 until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Atezolizumab + Bevacizumab + IO-108 1200 mg Q3W | EXPERIMENTAL | Participants will receive atezolizumab plus bevacizumab plus IO-108 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Atezolizumab + Bevacizumab + NKT2152 | EXPERIMENTAL | Participants will receive atezolizumab plus bevacizumab plus NKT2152 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. |
| Stage 1: Atezolizumab + Bevacizumab+ IO-108 1800 mg Q3W | EXPERIMENTAL | Participants will receive atezolizumab plus bevacizumab plus IO-108 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic andbiochemical data, local biopsy results (if available), and clinical status |
| Name | Type | Description |
|---|---|---|
| Atezolizumab | DRUG | Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle. |
| Bevacizumab 15 mg/kg | DRUG | Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle. |
| Tiragolumab | DRUG | Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle. |
| Tocilizumab | DRUG | Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle. |
| TPST-1120 | DRUG | TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle. |
| Tobemstomig 2100 mg | DRUG | Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle. |
| Bevacizumab 10 mg/kg | DRUG | Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle. |
| Tobemstomig 600 mg | DRUG | Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle. |
| Tobemstomig 1200 mg | DRUG | Tobemstomig will be administered at a dose of 1200 mg every 3 weeks. |
| ADG126 | DRUG | ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days). |
| IO-108 1800 mg | DRUG | IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle. |
| NKT2152 | DRUG | NKT2152 will be administered by mouth. |
| IO-108 1200 mg | DRUG | IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle. |
Inclusion Criteria: Stage 1 * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 7 days prior to randomization * Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically by American Ass...
Atezolizumab is an investigational immunotherapy being studied for the treatment of advanced liver cancers. It is part of a Phase 1 clinical trial evaluating multiple immunotherapy-based treatment combinations in patients with this condition. The drug is being developed by Adagene Inc. and is currently in clinical development.
Atezolizumab is a monoclonal antibody, classified as a -mab antibody. It is designed to target and modulate immune system pathways involved in cancer. The specific molecular target is not disclosed, but as an antibody-based therapy, it works by interacting with components of the immune system to potentially enhance anti-tumor responses.
Atezolizumab is being developed by Adagene Inc., a biopharmaceutical company. The company is publicly traded under the ticker symbol ADAG. Adagene is conducting clinical trials to evaluate the safety and efficacy of Atezolizumab in patients with advanced liver cancers.
Atezolizumab is currently in Phase 1 clinical development. It is being studied in an active, recruiting Phase 1 trial for advanced liver cancers. The drug is investigational and has not yet been approved by regulatory authorities. Its safety and efficacy are still being evaluated in clinical trials.
Atezolizumab is being evaluated in a Phase 1 clinical trial with the identifier NCT04524871. This study, titled 'A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)', is actively recruiting participants. The trial is randomized and active-controlled, with an estimated enrollment of 518 patients.
Atezolizumab is a distinct drug candidate developed by Adagene Inc. It is a monoclonal antibody being investigated for advanced liver cancers. No alternative names for this drug have been disclosed. It is currently in Phase 1 clinical trials and is not yet approved for any indication.